Dizal (688192.SH) Presents Latest Data on Golidocitinib and Birelentinib at 67th ASH Annual Meeting

Stock News12-09

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced the presentation of updated clinical data for two first-in-class drugs at the 67th American Society of Hematology (ASH) Annual Meeting. The company showcased new research findings on its highly selective JAK1 inhibitor golidocitinib (generic name: golidocitinib capsules) in T-cell lymphoma, along with the latest clinical results for the non-covalent LYN/BTK dual-target inhibitor birelentinib (DZD8586) in B-cell lymphoma treatment.

At the ASH conference, Dizal reported updated follow-up data from the study. At the recommended Phase III dose (RP3D) of 50mg, the overall response rate (ORR) reached 84.2%. Tumor responses were observed in patients who had previously received BTK inhibitors, Bcl-2 inhibitors, or BTK degraders, including those carrying classic BTK resistance mutations (C481X) or other BTK mutations (including kinase "inactive" mutations). The anti-tumor efficacy demonstrated durability with a favorable safety profile, and no new safety concerns emerged during follow-up.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135742635?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 15:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135742635","market":"sh","top_or_hot":-1,"title":"Dizal (688192.SH) Presents Latest Data on Golidocitinib and Birelentinib at 67th ASH Annual Meeting","media":"Stock News","content":"<p>Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced the presentation of updated clinical data for two first-in-class drugs at the 67th American Society of Hematology (ASH) Annual Meeting. The company showcased new research findings on its highly selective JAK1 inhibitor golidocitinib (generic name: golidocitinib capsules) in T-cell lymphoma, along with the latest clinical results for the non-covalent LYN/BTK dual-target inhibitor birelentinib (DZD8586) in B-cell lymphoma treatment.</p>\n<p>At the ASH conference, Dizal reported updated follow-up data from the study. At the recommended Phase III dose (RP3D) of 50mg, the overall response rate (ORR) reached 84.2%. Tumor responses were observed in patients who had previously received BTK inhibitors, Bcl-2 inhibitors, or BTK degraders, including those carrying classic BTK resistance mutations (C481X) or other BTK mutations (including kinase \"inactive\" mutations). The anti-tumor efficacy demonstrated durability with a favorable safety profile, and no new safety concerns emerged during follow-up.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal (688192.SH) Presents Latest Data on Golidocitinib and Birelentinib at 67th ASH Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal (688192.SH) Presents Latest Data on Golidocitinib and Birelentinib at 67th ASH Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-09 15:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced the presentation of updated clinical data for two first-in-class drugs at the 67th American Society of Hematology (ASH) Annual Meeting. The company showcased new research findings on its highly selective JAK1 inhibitor golidocitinib (generic name: golidocitinib capsules) in T-cell lymphoma, along with the latest clinical results for the non-covalent LYN/BTK dual-target inhibitor birelentinib (DZD8586) in B-cell lymphoma treatment.</p>\n<p>At the ASH conference, Dizal reported updated follow-up data from the study. At the recommended Phase III dose (RP3D) of 50mg, the overall response rate (ORR) reached 84.2%. Tumor responses were observed in patients who had previously received BTK inhibitors, Bcl-2 inhibitors, or BTK degraders, including those carrying classic BTK resistance mutations (C481X) or other BTK mutations (including kinase \"inactive\" mutations). The anti-tumor efficacy demonstrated durability with a favorable safety profile, and no new safety concerns emerged during follow-up.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1135742635","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135742635","pubTimestamp":1765266395,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced the presentation of updated clinical data for two first-in-class drugs at the 67th American Society of Hematology (ASH) Annual Meeting....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688192":"迪哲医药","BK0239":"医药制造"},"translate_title":"迪赛尔（688192.SH）在第67届ASH年会上展示Golidocitinib和Birelentinib最新数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688192":1},"content_text":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced the presentation of updated clinical data for two first-in-class drugs at the 67th American Society of Hematology (ASH) Annual Meeting. The company showcased new research findings on its highly selective JAK1 inhibitor golidocitinib (generic name: golidocitinib capsules) in T-cell lymphoma, along with the latest clinical results for the non-covalent LYN/BTK dual-target inhibitor birelentinib (DZD8586) in B-cell lymphoma treatment.\nAt the ASH conference, Dizal reported updated follow-up data from the study. At the recommended Phase III dose (RP3D) of 50mg, the overall response rate (ORR) reached 84.2%. Tumor responses were observed in patients who had previously received BTK inhibitors, Bcl-2 inhibitors, or BTK degraders, including those carrying classic BTK resistance mutations (C481X) or other BTK mutations (including kinase \"inactive\" mutations). The anti-tumor efficacy demonstrated durability with a favorable safety profile, and no new safety concerns emerged during follow-up.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135742635","isCrawlerRequest":true}